Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated (VRTX) — Form 144: Proposed sale of shares
AI-generated summary
Reshma Kewalramani, Officer and Director of Vertex Pharmaceuticals Incorporated Common Stock, filed to propose the sale of 11,866 shares of common stock with an aggregate market value of $6,307,134.98 through Fidelity Brokerage Services LLC. The proposed sale date is November 6, 2026. The plan for the sale was adopted on August 5, 2026.
Key facts
- Seller
- Kewalramani Reshma
- Relationship
- Officer, Director
- Shares to sell
- 11,866
- Market value
- $6,307,134.98
- Approximate sale date
- Nov 6, 2026
- Broker
- Fidelity Brokerage Services LLC
- Acquired (1)
- May 14, 2024 · ESPP Purchase
- Acquired (2)
- Feb 24, 2025 · Restricted Stock Vesting
- Acquired (3)
- May 14, 2025 · ESPP Purchase
- Acquired (4)
- Aug 6, 2025 · Restricted Stock Vesting
Rule 10b5-1 plan · adopted Aug 5, 2026
More VRTX filings
- 10-Q
Filed Nov 3, 2026
- 8-K
Filed Nov 2, 2026
- 4
Filed Oct 22, 2026
- 3
Filed Oct 22, 2026
- 8-K
Filed Oct 20, 2026
- 4
Filed Oct 19, 2026
Not investment advice. Summaries can contain errors; the SEC filing is the official record.